[PDF] Top 20 Phase I study of pemetrexed with sorafenib in advanced solid tumors
Has 10000 "Phase I study of pemetrexed with sorafenib in advanced solid tumors" found on our website. Below are the top 20 most common "Phase I study of pemetrexed with sorafenib in advanced solid tumors".
Phase I study of pemetrexed with sorafenib in advanced solid tumors
... of advanced non-small cell lung cancer and ...[1]. Pemetrexed has been shown to have more than one mechanism of action in tumor cells as illustrated by the continued anti-proliferative effect of the drug in ... See full document
14
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
... whose tumors had progressed after disease control of ≥ 12 weeks with erlotinib or gefitinib, and thereafter, ...the phase III IMPRESS study, gefitinib plus cisplatin and pemetrexed in patients ... See full document
10
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
... of solid tumor types, including non–small-cell lung cancer (NSCLC) [1], squamous cell carcinoma of the head and neck (SCCHN) [2], melanoma [3], bladder cancer [4], and renal cell carcinoma ...whose tumors ... See full document
11
A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors
... current Phase Ib, dose-finding study was conducted to evaluate the safety and tolerability of ruxolitinib in com- bination with gemcitabine with or without nab-paclitaxel in patients with advanced ... See full document
9
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.
... was 400 mg BID based on the observed safety/tolerability, PK and PD profiles. The potential for gastrointestinal and hematological toxicities, particularly neutropenia and thrombocytopenia, should be considered when ... See full document
28
A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
... Partial response was reported in one NSCLC patient with unknown EGFR status. One NSCLC patient with SD lasting ≥ 6 months, and who had a mutation in EGFR had progressed after 15-month gefitinib treatment; he then ... See full document
11
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
... this study, although the limitation of this study was that induction of HSP70 was not considered in direct relation to antitumor effect, as relationship between client protein reduction and antitumor effect ... See full document
26
A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
... This phase 1, multicenter, open-label study was conducted at a total of 8 study sites (3 study sites in the United States and 5 Innovative Therapies for Children with Cancer [ITCC] Consortium ... See full document
12
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
... Notably, in this heavily pretreated population, six pa- tients (6/18, 33.3%) with a variety of solid tumors, having received prior anti-angiogenic agents, also showed pro- longed clinical benefits. While ... See full document
10
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.
... The study was sponsored by Merck & Co., Inc, Kenilworth, New Jersey, USA. Andrew J. Wagner has a consulting or advisory role with Eli Lilly & Co. and EMD Serono; he also has research funding to institution ... See full document
40
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
... a phase I study of 35 patients with advanced solid tumors by employing a dose-escalating design ...early phase trials of buparlisib in patients with relapsed/refractory ... See full document
17
<p>Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development</p>
... a phase I dose- escalation trial examining the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single-agent pexidar- tinib in patients with solid tumors ...3+3 study, each ... See full document
12
A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
... Chinese patients older than 18 years of age with histologi- cally or cytologically proven metastatic or locally advanced solid tumor(s), who progressed on standard therapy, or for whom standard therapy does ... See full document
6
A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
... Eligible patients were aged ≥ 18 years with advanced, recurrent or metastatic solid malignancies. Patients were also required to have adequate organ function, Eastern Cooperative Oncology Group performance ... See full document
11
A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors
... (UANL) were developed for the first time in the People’s Republic of China. The intravenous (IV) administration of UANL is considered to improve bioavailability because the nanoparticles bypass the stomach. To date, a ... See full document
8
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
... in Phase I studies, is 25 mg ...in Phase I study and confirmed in the subsequent Phase II and III studies, are hypertension, proteinuria, and gastrointestinal symptoms such as ... See full document
11
Clinical development of nintedanib for advanced non-small-cell lung cancer
... reversible on cessation of treatment. Therefore, nintedanib was found to have an acceptable tolerability profile for Japanese patients with advanced solid tumors at doses up to 200 mg twice daily, ... See full document
6
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.
... Supplementary material Page 9 stabilisation (no change), and the remaining patient with minimal scores pre- and post-treatment. Therefore, in vivo target inhibition of AT9283 in the form of a reduction in pHH3 could not ... See full document
31
Second-line combination therapies in nonsmall cell lung cancer without known driver mutations
... This study led to the approval of erlotinib as second- and third-line treatment for advanced NSCLC, independent of the EGFR mutational status, which at the time was not routinely tested ...docetaxel, ... See full document
12
Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol
... with tumors lacking specific DDR ...treating tumors harbor- ing BRCA1 or BRCA2 mutations represents the first drug based on this ...a phase I clinical study using olaparib, a PARP ... See full document
7
Related subjects